SNGLR Capital
SNGLR Capital is a venture capital firm established in 2021 and located in Zug, Switzerland. The firm focuses on investing in early-stage technology startups primarily in Europe, targeting sectors with high growth potential such as longevity, smart mobility, and smart cities. SNGLR Capital emphasizes the use of advanced technologies, including artificial intelligence, blockchain, data (IoT and APIs), 5G, and robotics, to support its investment strategy. The firm collaborates closely with entrepreneurs throughout their journey, leveraging the experience of its team, which includes former founders, early-stage investors, and advisors. Additionally, SNGLR Capital engages with selected corporate venture units and consulting firms to enhance market access and provide technology insights through its XLabs development program.
Cellestia
Venture Round in 2021
Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.